Rapport Therapeutics Raises More Than $400 Million Through Stock, Notes, and Private Placement Offerings

What happened

Rapport Therapeutics raised more than $400 million through stock, notes, and private placement offerings, closing on October 30, 2026. The package included $172.5 million of convertible notes and a $30 million private placement, with the money mainly funding clinical trials and research.

Confirmed

Global impact / market context

The new money gives Rapport a larger cash balance to pay for clinical trials and research, which are costly and slow. Convertible notes are borrowed money that can later become stock, so Rapport adds funding now while possibly limiting future borrowing costs and share dilution.

Analyst inference

Investors can compare the financing mix: stock sales bring in cash but dilute existing owners, while notes add debt that matures in 2032. The stated use for trials and general corporate purposes links the raise to drug development timelines rather than near-term revenue.

Analyst inference

What to watch

1. The convertible senior notes carry a 2.25% interest rate and mature on December 1, 2032, unless converted, redeemed, or repurchased earlier. Confirmed
2. Watch whether Rapport spends the estimated net proceeds as planned on clinical trials, research and development, and general corporate purposes. Proposed
3. Track trial progress and cash needs, because costs can rise before any product revenue, and the convertible notes may later convert into stock and dilute ownership. Analyst inference

Evidence

• Original source link unavailable